Columbia Laboratories to Present at Rodman & Renshaw Healthcare
Conference in NYC on November 7, 2006
LIVINGSTON, NJ— October 26 — Robert S. Mills, president and chief executive officer of Columbia Laboratories, Inc. (NASDAQ: CBRX), will present at the Rodman & Renshaw 8th Annual Healthcare Conference.
Date: Tuesday, November 7, 2006 Time: 4:15 p.m. Eastern Time Venue: The New York Palace Hotel, New York City Live webcast: www.columbialabs.com, under “Events” in the Investor section
This presentation will be archived for 90 days on Columbia Laboratories’ website, www.columbialabs.com, under “Events” in the Investor section.
About Columbia Laboratories
Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company dedicated to the development and commercialization of reproductive healthcare and endocrinology products that use its novel bioadhesive drug delivery technology. Columbia markets PROCHIEVE® 8% (progesterone gel) for progesterone supplementation as part of an Assisted Reproductive Technology treatment for infertile women with progesterone deficiency and PROCHIEVE 4% (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT® (testosterone buccal system) for the treatment of hypogonadism in men. The Company recently completed enrollment in a large-scale pivotal Phase III study to evaluate the possible utility of PROCHIEVE 8% (progesterone gel) in the prevention of recurrent preterm birth. This randomized, double-blind, placebo-controlled trial involves 669 patients at more than 60 centers globally. The Company’s additional research and development programs include a vaginally-administered lidocaine product to treat dysmenorrhea. For more information, please visit www.columbialabs.com.
PROCHIEVE® and STRIANT® are registered trademarks of Columbia Laboratories, Inc.
###